肝动脉置管化疗栓塞在不可切除结肠癌肝转移的临床疗效评价  

The evaluation of the clinical effect of hepatic arterial cathetering chemoembolization on patients with unresectable colorectal liver metastases

作　　者：唐仪[1] 杨厚林[1] 吴少杰[1] 方主亭[1] 陈良生[1] 

机构地区：[1]福建省立医院放射介入科,福州350001

出　　处：《中华临床医师杂志（电子版）》2014年第3期66-69,共4页Chinese Journal of Clinicians(Electronic Edition)

摘　　要：目的探讨经肝动脉置管化疗栓塞对不可切除的结肠癌肝转移(CRCLM)肝内转移灶的疗效。方法回顾性分析不可切除的CRCLM在2010年6月至2013年6月采用超选择经肝动脉置管化疗栓塞术41例患者,和2007年3月至2010年5月单纯经肝动脉灌注化疗栓塞50例患者,比较各组之间的疗效、有效率、临床获益率及不良反应。结果肝动脉置管化疗栓塞组和肝动脉灌注化疗栓塞组的有效率分别是56.1%和38.0%,临床获益率分别是87.8%和66.0%,差异有统计学意义(P<0.05)。两组患者的化疗不良反应以白细胞下降、恶心呕吐、末梢神经炎、静脉炎、腹泻和口腔黏膜炎为主。两组间不良反应的比较差异无统计学意义(P>0.05)。结论经肝动脉置管FOLFOX4方案化疗栓塞术治疗不可切除的CRCLM有一定的疗效,其有效率和临床获益率较单纯的肝动脉化疗栓塞术有优势。Objective To investigate the effect of hepatic arterial cathetering chemoembolization on patients with unresectable colorectal liver metastases. Methods 41 cases of unresectable colorectal liver metastases from June 2010 to June 2013 who were treated by hepatic artery cathetering chemoembolization were compared with 50 cases from March 2007 to May 2010 who undergo via hepatic artery perfusion chemoembolization.The amount of effective rate, clinical benefit rate and adverse reaction were compared between two groups. Results The amount of effective rate and clinical benefit rate were 56.1%, 87.8%, respectively, in the hepatic artery cathetering chemoembolization and 38.0%, 66.0% in the hepatic artery perfusion chemoembolization respectively. The differences were respectively statistically significant（P〈0.05）. Adverse reaction of chemotherapy include white blood cells decline, nausea, vomiting, peripheral neuritis, phlebitis, diarrhea, and oral mucositis.The adverse reaction between the two groups has no statistical significance（P〉0.05）. Conclusion Patients with unresectable colorectal liver metastases can benefit from hepatic arterial cathetering FOLFOX4 chemotherapy and embolization, especially in the effective rate and clinical benefit rate.

关 键 词：结直肠肿瘤 肿瘤转移 化学疗法 肿瘤 局部灌注 治疗效果 FOLFOX4 

分 类 号：R735.3[医药卫生—肿瘤]